The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

Huang, Wei; Luo, Jiayu; Wen, Jianbo; Jiang, Mingjun

doi:10.3389/fsurg.2022.898304

Cited by 28 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, SII, an index based on blood tests, has shown great potential as a complementary item for the prediction of survival in patients with malignancies. The impact of SII on the prognosis of solid tumors, including breast cancer [ 43 ], pancreatic cancer [ 44 ], lung cancer [ 45 ], and cervical cancer [ 46 ], as well as solid tumors of the urinary system, such as bladder cancer [ 47 ], has been reported in many studies. Several studies of SII have been summarized in such systematic reviews and meta-analyses, which provided penetrating insight into the association between SII and solid tumors, such as colorectal cancer [ 48 ], uterine cervical cancer [ 49 ], breast cancer [ 24 ], and pancreatic cancer [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Meng

Yang

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Background The systemic immune-inflammation index (SII) is a novel biomarker to predict the prognosis of some malignant tumors based on neutrophil, platelet, and lymphocyte counts. Evidence is scarce about the prognostic value of SII for prostate cancer patients. This systematic review and meta-analysis was conducted to explore the prognostic value of the SII in prostate cancer. Methods The PubMed, Embase, Web of Science, and Cochrane Library (CENTRAL) databases were searched to determine eligible studies from inception to August 15, 2022. Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to pool the results. Statistical analyses were conducted by using Stata 17.0 software. Results A total of 12 studies with 8083 patients were included. The quantitative synthesis showed that a high SII was related to poor overall survival (OS) (HR = 1.44, 95% CI 1.23–1.69, p < 0.001). Furthermore, a subgroup analysis showed that a high SII was associated with poor OS in the groups of any ethnicity, tumor type, and cutoff value. An increased SII was also associated with inferior progression-free survival (PFS) (HR = 1.80, 95% CI 1.27–2.56, p = 0.001). In the subgroup analysis, a high SII value was related to poor PFS in Asian patients (HR = 4.03, 95% CI 1.07–15.17, p = 0.04) and a cutoff value > 580 (HR = 1.19, 95% CI 1.04–1.36, p = 0.01). Conclusion Based on the current evidence, a high pretreatment SII may be associated with poor OS and PFS. The SII may serve as an important prognostic indicator in patients with prostate cancer. More rigorously designed studies are needed to explore the SII and the prognosis of prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Meng

Yang

et al. 2023

J Transl Med

View full text Add to dashboard Cite

show abstract

“…As a result, it was determined that patients with a high index level had worse survival than patients with a lower index. It was also determined that patients with the II-III stage of the disease had a higher SII index [12]. Obtained data also correlated with the investigation of Qi [13] and Tong [14].…”

Section: Figure 1 -Roc Curve Analysis For Optimal Cut-off Value Of In...mentioning

confidence: 59%

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Smorodska

Moskalenko

Kononenko

et al. 2022

EUMJ

View full text Add to dashboard Cite

Introduction. Prediction of lung cancer recurrence is one of the most urgent problems of modern oncology. Scientists are trying to find independent predictors that will help intensify, personalize the patient's treatment, and prevent the disease relapse on time. The study aimed to find indicators of inflammation that could be independent predictors of disease recurrence in patients with surgically resected non-small cell lung cancer. Materials and methods. The study was conducted retrospectively. The study group included 104 patients with non-small cell lung cancer who received surgical treatment and adjuvant chemotherapy or chemoradiotherapy from 2014 to 2018 at the Sumy Regional Clinical Oncology Dispensary. Based on the results of the blood count tests, the inflammation indices were calculated before chemotherapy or chemoradiotherapy and one month after their completion. Systemic inflammatory response index (SIRI), systemic inflammatory index (SII), neutrophil/lymphocyte ratio (NLR), platelets/lymphocytes ratio (PLR), lymphocyte/monocyte ratio (LMR), monocyte/lymphocyte ratio (MLR) were calculated. Using ROC analysis, cut-off points were found. Cox regression was used to find independent predictors of lung cancer recurrence. Results. During the observation period, relapse of the disease was recorded in 42 (40.4%) patients. The average recurrence-free survival was 56.3 months, range of 4–84.0 months (95% CI = 46.866–65.683). Before chemo- or chemoradiation therapy, the cut-off points for NLR1, PLR1, MLR1, LMR1, SII1, and SIRI1 were 1.80, 126.35, 0.22, 4.80, 521.22 and 0.96, respectively. Cut-off points for NLR2, PLR2, MLR2, LMR2, SII2, and SIRI2 at stage one month after completing courses of chemotherapy or chemoradiotherapy were 1.33, 153.80, 0.26, 3.98, 450.10 and 0.82 respectively. According to ROC analysis, only PLR1, SII1, LMR1, and LMR2 indices are reliable and can be used in further Cox regression analysis. Univariant Cox regression showed that LMR1 and SII1 were significantly associated with disease recurrence. Multivariate Cox regression identified SII1 as the only independent predictor of disease recurrence. Conclusions. Among numerous inflammation indices as an independent predictor for disease recurrence in non-small cell lung cancer patients who received surgical treatment and chemotherapy or chemoradiotherapy, only systemic inflammation index (SII1) at the stage before chemotherapy or chemoradiotherapy can be used. Indicators above 521.22 could be a predictor of high-risk recurrence of lung cancer.

show abstract

“…As a typical inflammation-associated cancer, NSCLC could use the Systemic Immune Inflammatory Index as a promising prognostic biomarker. [ 41 ] NSCLC patients had significant up-regulated levels of TNFα, which is also in correlation with the occurrence and prognosis of cancer pain in patients. [ 42 ] IL-17 and chondrolectin were reported to promote the proliferation and growth of NSCLC.…”

Section: Discussionmentioning

confidence: 99%

The mechanism of Bai He Gu Jin Tang against non-small cell lung cancer revealed by network pharmacology and molecular docking

et al. 2022

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related burden and deaths, thus effective treatment strategies with lower side effects for NSCLC are urgently needed. To systematically analyze the mechanism of Bai He Gu Jin Tang (BHGJT) against NSCLC by network pharmacology and molecular docking. Methods: The active compounds of BHGJT were obtained by searching the Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine and Encyclopaedia of Traditional Chinese Medicine. Search tool for interactions of chemicals was used for acquiring the targets of BHGJT. The component-target network was mapped by Cytoscape. NSCLC-related genes were obtained by searching Genecards, DrugBank and Therapeutic Target Database. The protein-protein interaction network of intersection targets was established based on Search Tool for Recurring Instances of Neighboring Genes (STRING), and further, the therapeutic core targets were selected by topological parameters. The hub targets were transmitted to Database for Annotation, Visualization and Integrated Discovery for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Finally, AutoDock Vina and MglTools were employed for molecular docking validation. Results: Two hundred fifty-six compounds and 237 putative targets of BHGJT-related active compounds as well as 1721potential targets of NSCLC were retrieved. Network analysis showed that 8 active compounds of BHGJT including kaempferol, quercetin, luteolin, isorhamnetin, beta-sitosterol, stigmasterol, mairin and liquiritigenin as well as 15 hub targets such as AKR1B10 and AKR1C2 contribute to the treatment of BHGJT against NSCLC. GO functional enrichment analysis shows that BHGJT could regulate many biological processes, such as apoptotic process. Three modules of the endocrine related pathways including the inflammation, hypoxia related pathways as well as the other cancer related pathways based on Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis might explain the biological mechanisms of BHGJT in treating BHGJT. The results of molecular docking verified that AKR1B10 and AKR1C2 had the strongest binding activity with the 8 key compounds of NSCLC. Conclusion: Our study reveals the mechanism of BHGJT in treating NSCLC involving multiple components, multiple targets and multiple pathways. The present study laid an initial foundation for the subsequent research and clinical application of BHGJT and its active compounds against NSCLC.

show abstract

The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

Cited by 28 publications

References 35 publications

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

The mechanism of Bai He Gu Jin Tang against non-small cell lung cancer revealed by network pharmacology and molecular docking

Contact Info

Product

Resources

About